Nagamori Memorial Center of Innovative Cancer Therapy and Research Equipped with Hitachi’s Radiation Therapy Systems Started Operation
Hitachi provides comprehensive services including operation support and facility operation related to cutting-edge radiation therapy system
Tokyo, April 1, 2019 --- Hitachi, Ltd. (TSE: 6501, "Hitachi") announced today that the radiation therapy started on April 1, 2019 at Nagamori Memorial Center of Innovative Cancer Therapy and Research at Kyoto Prefectural University of Medicine (“Nagamori Memorial Center of Innovative Cancer Therapy and Research “) which introduced Hitachi’s radiation therapy systems.
For Nagamori Memorial Center of Innovative Cancer Therapy and Research Hitachi provides comprehensive services including operation support and facility operation related to radiation therapy systems of the proton therapy system and X-ray therapy system TomoTherapy System Radixact. Those services will enable the staff of Nagamori Memorial Center of Innovative Cancer Therapy and Research to concentrate on medicine and to provide highly advanced, cutting-edge radiation oncology treatment.
Nagamori Memorial Center of Innovative Cancer Therapy and Research is one of the most advanced cancer therapy facilities that was established by the endowment of S. N. Kosan Corporation owned by Mr. Shigenobu Nagamori, the Founder, Chairman and CEO of Nidec Corporation, with an aim to contribute to Kyoto prefecture and the local residents. The facility is operated as the radiation therapy facility of Kyoto Prefectural University of Medicine, which consolidates the most advanced therapy systems including the proton therapy system at one site.
As highly advanced medical equipment, the radiation therapy systems require regular maintenance. In addition, as the first proton therapy site in Kyoto prefecture, there has been operational needs such as public awareness activities for the citizens and clinical alignment with the neighboring medical facilities for prevalence of the therapy.
Hitachi’s particle therapy system has been introduced by the world-class renowned facilities, greatly valued its proven reliability and experiences based on the track record of the system uptime of more than 98% and the long-term, fulfilling customer support system. Also, Hitachi has been offering operational support service for customer’s radiation oncology department since 2000 and has provided engineering support for introduction and stable operation of the systems required for radiation oncology examination at the contracted facilities, operation support including asset management and planning of equipment introduction.
After the proven experiences of the particle therapy system and of those operational support services for the radiation oncology department were highly evaluated, Hitachi provides the comprehensive support for operation and maintenance of the proton therapy system, operation of X-ray therapy system and facility operation as follows:
Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society’s challenges, combining its operational technology, information technology, and products/systems. The company’s consolidated revenues for fiscal 2017 (ended March 31, 2018) totaled 9,368.6 billion yen ($88.4 billion). The Hitachi Group is an innovation partner for the IoT era, and it has approximately 307,000 employees worldwide. Through collaborative creation with customers, Hitachi is deploying Social Innovation Business using digital technologies in a broad range of sectors, including Power/Energy, Industry/Distribution/Water, Urban Development, and Finance/Social Infrastructure/Healthcare. For more information on Hitachi, please visit the company's website at http://www.hitachi.com.